Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis

Highlights • Receptor tyrosine kinases (RTKs) may facilitate tumor progression if activated aberrantly. • The effects on prognosis of overexpression of other RTKs beyond HER2 is unknown in breast cancer. • Our results show that overexpression of various RTKs is associated with poor outcomes. • Worse...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2014-10, Vol.40 (9), p.1048-1055
Hauptverfasser:	Templeton, Arnoud J, Diez-Gonzalez, Laura, Ace, Olga, Vera-Badillo, Francisco, Šeruga, Boštjan, Jordán, Joaquín, Amir, Eitan, Pandiella, Atanasio, Ocaña, Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Breast cancer Breast Neoplasms - enzymology Breast Neoplasms - mortality Female Gynecology. Andrology. Obstetrics Hematology, Oncology and Palliative Medicine Humans Mammary gland diseases Medical sciences Meta-analysis Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Odds Ratio Overexpression Pharmacology. Drug treatments Predictive Value of Tests Prognosis Receptor Protein-Tyrosine Kinases - metabolism Receptor tyrosine kinase Receptor, Epidermal Growth Factor - metabolism Receptor, Fibroblast Growth Factor, Type 2 - metabolism Receptor, Fibroblast Growth Factor, Type 3 - metabolism Targeted therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Receptor tyrosine kinases (RTKs) may facilitate tumor progression if activated aberrantly. • The effects on prognosis of overexpression of other RTKs beyond HER2 is unknown in breast cancer. • Our results show that overexpression of various RTKs is associated with poor outcomes. • Worse OS was seen with overexpression of FGFR 2/3 and EGFR. • We suggests the clinical evaluation of combination of agents against RTKs or relevant oncogenic nodes.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2014.08.003